Latest News

Ampio Pharmaceuticals to Host Business Update Call with Chairman and CEO Mike Martino on Wednesday, Dec. 1

Date: November 29, 2021 | READ MORE >

Ampio Pharmaceuticals Announces Shareholder / Business Update Call with its CEO & Chairman, Michael Martino

Date: November 23, 2021 | READ MORE >

Board Member Michael Martino to Become Interim Chairman and CEO of Ampio Pharmaceuticals, Mike Macaluso to Take Medical Leave

Date: November 22, 2021 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides Business Update

Date: November 10, 2021 | READ MORE >

Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Business Update

Date: October 28, 2021 | READ MORE >

Ampio Pharmaceuticals Strengthens Management Team and Board of Directors

Date: October 13, 2021 | READ MORE >

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Date: September 21, 2021 | READ MORE >

Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)

Date: September 15, 2021 | READ MORE >

Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of Action

Date: August 13, 2021 | READ MORE >

Ampio Pharmaceuticals Reminds Stockholders to Vote Shares in Advance of 2021 Annual Meeting

Date: August 12, 2021 | READ MORE >

Ampio Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

Date: August 11, 2021 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Date: August 4, 2021 | READ MORE >

Ampio Pharmaceuticals to Present at the American College of Toxicology 42nd Annual Meeting

Date: July 29, 2021 | READ MORE >

Ampio Pharmaceuticals to Present at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA)

Date: July 28, 2021 | READ MORE >

Ampio Pharmaceuticals to Present at Aspen Lung Conference

Date: July 27, 2021 | READ MORE >

Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Business Update

Date: July 14, 2021 | READ MORE >

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Date: June 25, 2021 | READ MORE >

Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® Index

Date: June 18, 2021 | READ MORE >

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAK

Date: June 17, 2021 | READ MORE >

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Date: June 15, 2021 | READ MORE >